Progesterone Differentially Regulates the Membrane-Type Matrix Metalloproteinase-1 (MT1-MMP) Compartment of proMMP-2 Activation in MG-63 Cells

Osteoblast-derived matrix metalloproteinases (MMPs) are considered to play a crucial role in bone formation and initiation of bone resorption by degrading the bone matrix. MMP-2 is constitutively secreted in a latent zymogen by osteoblasts, and requires the process of activation mediated by membrane-type matrix metalloproteinase-1 (MT1-MMP)/tissue inhibitor of metalloproteinase (TIMP-2) complex in the cell surface. Bone is one target tissue for progestins. In the present study, we observed the effects of progesterone on proMMP-2 activation and MT1-MMP expression, and also TIMP-2 levels in osteoblastic MG-63 cells. Gelatin zymograms and ELISA showed that progesterone have no effects on proMMP-2 activation. Using Western immunoblot analysis, we unexpectedly found that treatment with increasing doses of progesterone in MG-63 cells caused a dose-dependent increase in expression of MT1-MMP protein, and after 48 h treatment, progesterone at 10^-8 M increased MT1-MMP protein level. Confocal immunohistochemistry analysis also confirmed that progesterone induced MT1-MMP expression in MG-63 cells. The results of Northern blot analysis showed that progesterone at 10^-8 M increased MT1-MMP protein levels after 48 h treatment. We also found that TIMP-2 levels were undetectable in MG-63 cells. In conclusion, progesterone increases MT1-MMP protein and mRNA levels in MG-63 cells, but has no effects on proMMP-2 activation, which is partly attributable to the undetectable levels of tissue inhibitor of metalloproteinase-2 (TIMP-2). Our studies suggest that TIMP-2 is involved in proMMP-2 activation, and regulation of MT1-MMP by progesterone may contribute to its actions on bone formation.

Progesterone - MT1-MMP - proMMP-2 - TIMP-2

References

• 1 Christiansen C, Nilas L, Riis B J, Rodbro P, Deftos L J. Uncoupling of bone formation and resorption by combined oestrogen and progesterone therapy in postmenopausal osteoporosis.  Lancet. 1985;  2 800-801
• 2 MacNamara P, O'Shaughnessy C, Manduca P, Loughrey H C. Progesterone receptors are expressed in human osteoblast-like cell lines and in primary human osteoblast cultures.  Calcif Tissue Int. 1995;  57 436-441
• 3 Rifas L, Fausto A, Scott M J, Avioli L V, Welgus H G. Expression of metalloproteinase and tissue inhibitor of metalloproteinase in human osteoblast-like cells: metalloproteinase biosynthesis.  Endocrinology. 1994;  134 213-221
• 4 Westermarck J, Kahari V. Regulation of matrix metalloproteinase expression in tumor invasion.  FASEB J. 1999;  13 781-792
• 5 Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M. A matrix metalloproteinase expressed on the surface of invasive tumor cells.  Nature. 1994;  370 61-65
• 6 Zuker S, Drews M, Conner C, Foda H D, DeClerck Y A, Langley K E, Bahou W F, Docherty A JP, Cao J. Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1-matrix metalloproteinase (MT1-MMP).  J Biol Chem. 1998;  273 1216-1222
• 7 Kanayma H O, Yokota K Y, Kurokawa Y, Murakami Y, Nishitani M, Kagwa S. Prognostic values of matrix metalloproteinase and tissue inhibitor of metalloproteinase-2 expression in bladder cancer.  Cancer. 1998;  82 1359-1366
• 8 Migita K, Eguchi K, Kawabe Y, Ichinose Y, Tsukada T, Aoyagi T, Nakamura H, Nagataki S. TNF-α-mediated expression of membrane-type matrix metalloproteinase in rheumatoid synovial fibroblasts.  Immunology. 1996;  89 553-557
• 9 Wang Z, Juttermann R, Soloway P D. TIMP-2 is required for efficient activation of proMMP-2 in vivo. .  J Biol Chem. 2000;  275 26 411-26 415
• 10 Ko Y C, Langley K E, Mendiaz E A, Parker V P, Taylor S M, DeClerck Y A. The C-terminal domain of tissue inhibitor of metalloproteinases-2 is required for cell binding but not for antimetalloproteinase activity.  Biochem Biophys Res Commun. 1997;  236 100-105
• 11 Emmert-Buck M R, Emonard H P, Corcoran M L, Foidart J M, Stetler-Stevenson W G. Cell surface binding of TIMP-2 and pro-MMP-2/TIMP-2 complex.  FEBS Lett. 1995;  364 28-32
• 12 McClelland P, Onyia J E, Miles R R, Tu Y, Liang J, Harvey A K, Chandrasekhar S, Hock J M, Bidwell J P. Intermittent administration of parathyroid hormone (1 - 34) stimulates matrix metalloproteinase-9 (MMP-9) expression in rat long bone.  J Cell Biochem. 1998;  70 391-401
• 13 Karsdal M A, Larsen L, Delaisse J, Bonewald L F, Foged N T, Lochter A. Osteoblasts, but not osteocytes, depend on matrix metalloproteinases and TGF-β for survival: implications for conversion of osteoblasts into osteocytes.  J Bone Miner Res. 2000;  15 (Suppl 1) S267
• 14 Holmbeck K, Bianco P, Caterina J, Yamada S, Kromer M, Kuznetsov S A, Mankani M, Robey P G, Poole A R, Pidoux I, Ward J M, Birkedal-Hansen H. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover.  Cell. 1999;  99 81-92
• 15 Shofuda K, Yasumitsu H, Nishihashi A, Miki K, Miyazaki K. Expression of three mebrane-type matrix metalloproteinase (MT-MMPs) in rat vascular smooth muscle cells and characterization of MT3-MMPs with and without transmembrane domain.  J Biol Chem. 1997;  272 9749-9754
• 16 Nguyen M, Arkell J, and Jackson C J. Thrombin rapidly and efficiently activates gelatinase A in human microvascular endothelial cells via a mechanism independent of active MT1 matrix metalloproteinase.  Lab Invest. 1999;  79 467-475